Allianz Asset Management
ADVM

Allianz Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Allianz Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,047
Closed -$212K – 2530
2021
Q2 		$212K Sell
6,047
-17,097
-74% -$921K ﹤0.01% 2341
2021
Q1 		$2.28M Sell
23,144
-500
-2% -$60K ﹤0.01% 1355
2020
Q4 		$2.56M Sell
23,644
-3,365
-12% -$416K ﹤0.01% 1247
2020
Q3 		$2.78M Buy
27,009
+3,048
+13% +$456K ﹤0.01% 1152
2020
Q2 		$5M Sell
23,961
-6,260
-21% -$1.11M 0.01% 1215
2020
Q1 		$2.95M Buy
30,221
+3,539
+13% +$413K ﹤0.01% 1391
2019
Q4 		$3.07M Buy
26,682
+19,649
+279% +$1.73M ﹤0.01% 1695
2019
Q3 		$383K Buy
+7,033
New +$793K ﹤0.01% 2453
2015
Q2 		– Sell
-6,401
Closed -$2.59M – 2355
2015
Q1 		$2.59M Buy
+6,401
New +$2.71M ﹤0.01% 1443

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management's ADVM Position: Q3 2021 in Review

Allianz Asset Management sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 6,047 shares — an estimated $212K sold.

Allianz Asset Management first reported a position in ADVM in Q1 2015 and held it in 9 quarters. The position peaked at $5M in Q2 2020. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • Allianz Asset Management reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Allianz Asset Management sold 6,047 Adverum Biotechnologies shares in Q3 2021, an estimated $212K.
  • Allianz Asset Management first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 9 quarters.
  • Allianz Asset Management's Adverum Biotechnologies position peaked at $5M in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on Allianz Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.